Search
mRNA-3927
go.drugbank.com/drugs/DB17669InvestigationalmRNA-3927 is an investigational mRNA therapy that consists of two mRNAs that encode for the alpha and beta subunits of the mitochondrial enzyme propionyl-CoA carboxylase (PCC) encapsulated within a lipid
NOV-002
go.drugbank.com/drugs/DB05393InvestigationalNOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy.
IDD-1
go.drugbank.com/drugs/DB05439ExperimentalAs with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related antigen.
9MW3011
go.drugbank.com/drugs/DB24999InvestigationalThe drug is an anti-TMPRSS6 (Transmembrane Serine Protease 6, also known as Matriptase-2) monoclonal antibody.[L54591, L54596]
3-Acetylpyridine Adenine Dinucleotide
go.drugbank.com/drugs/DB03363ExperimentalIt is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)
SRP 299
go.drugbank.com/drugs/DB05440ExperimentalMycobacterium vaccae is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate Th2
XC221
go.drugbank.com/drugs/DB16503InvestigationalXC221 was investigated in clinical trials to treat patients with respiratory infections, including influenza, COVID-19, and other acute viral upper respiratory infections.
Valbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigationalThe reduction in chorea severity was observed as early as 2 weeks after starting treatment with an initial dose of 40 mg.[L47910]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates